Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials
about
Acetylcysteine for preventing contrast-induced nephropathyAcetylcysteine for preventing contrast-induced nephropathyAcute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies)Present and future in the treatment of diabetic kidney diseaseProphylaxis of contrast-induced nephrotoxicityRadiographic contrast-media-induced acute kidney injury: pathophysiology and prophylactic strategiesTherapeutic Targets of Human AKI: Harmonizing Human and Animal AKIAntioxidant effect of Phyllanthus emblica extract prevents contrast-induced acute kidney injuryCombination of hemoglobin and left ventricular ejection fraction as a new predictor of contrast induced nephropathy in patients with non-ST elevation myocardial infarction.Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine.Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial.Efficacy of preventive interventions for iodinated contrast-induced acute kidney injury evaluated by intrarenal oxygenation as an early marker.N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.Risk of Acute Kidney Injury, Dialysis, and Mortality in Patients With Chronic Kidney Disease After Intravenous Contrast Material Exposure.Effectiveness of N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsIntravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trialShort-Term High-Dose Vitamin E to Prevent Contrast Medium-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Elective Coronary Angiography: A Randomized Placebo-Controlled TrialPharmacological strategies to prevent contrast-induced acute kidney injury.Renal denervation: transition from pathophysiology to clinical practice.The prevention of contrast-induced nephropathy.Accuracy of point-of-care serum creatinine devices for detecting patients at risk of contrast-induced nephropathy: a critical overview.Contrast-Induced Nephropathy: An "All or None" Phenomenon?Oral N-acetylcysteine for prophylaxis of contrast-induced nephropathy in patients following coronary angioplasty: A meta-analysis.Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY tA double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.Drug-Induced Kidney Injury in the Elderly.N-acetylcysteine in contrast-induced acute kidney injury: clinical use against principles of evidence-based clinical medicine!Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guidelinesProtective effect of salidroside on contrast-induced nephropathy in comparison with N-acetylcysteine and its underlying mechanism.Intravenous N-acetylcysteine for the PRevention Of Contrast-induced nephropathy - a prospective, single-center, randomized, placebo-controlled trial. The INPROC trial.Predictive factors for contrast-induced acute kidney injury in high-risk patients given N-acetylcysteine prophylaxis
P2860
Q24187683-E11E50EA-A531-4475-9EC0-1ABEF06E8817Q24194049-8AF08AAA-D374-4B7B-95FF-118680BDAD99Q26745670-909BFA74-6486-4724-8492-3AF100D20AFBQ26864133-FB8DBB30-718A-43F0-AAE8-CDB27203D9CDQ27012899-7F5305F0-1B39-4FCE-9692-51B37C45DD4BQ27021421-3068DE00-1D84-4095-9988-6963A975AD7EQ30278440-E4FA1D44-8FEC-48DF-8AF0-4E1EBCD6D5EFQ33712773-5AD4D4BA-EF5A-4324-A2F7-A1092B4CA243Q33793946-FB2BC866-9331-4CE4-B2DC-CDA9F0B6B9A3Q33843623-3BB3EC7A-991A-441F-A3E9-14CC5C45D0D6Q34257105-7B24EC89-FEEF-4169-B143-F87555FCD2B4Q35751549-7C87C423-EC0A-497C-9259-26B903225B4CQ35803600-D2167397-4A3F-4919-AE57-BBDE2F729355Q35997843-427E48F8-5A31-4DF6-8019-643E4EC873B6Q36143434-3D321920-6000-41A1-8FC9-53BBE2D58BD1Q36262721-A99862AD-E861-4887-977A-15D861F80715Q37090807-35B95A58-6C4A-425A-8038-29A03578D957Q37639849-752DF88A-760B-4FE7-BB3A-07D29EA586EDQ38176764-E4671F25-901E-4339-A4C3-CD43E534A73CQ38226255-D7BBDFC9-C0F2-4C1F-96D4-C138DFE24383Q38230626-67C7329C-4CB4-4EB9-B17F-443F42B5A82CQ38250041-B25E88E3-573F-4D66-A382-C68815A94BBEQ38623589-11020456-78C8-4FA0-A8C2-FA8A3141DCB1Q41374870-698ED4D8-52AE-4438-B096-97A835FE3C87Q44035534-085F8C1D-9D64-4F73-B3AB-04B8F0E21BA1Q45065480-9B63E559-7522-45B5-B47B-96A1A500D1D4Q46320506-1B2E2C45-4563-4015-9027-274D518BA479Q50054523-EDED92CC-4AD6-4B51-AD1E-A55B1A2E2B55Q53543544-71029FBF-2265-49FF-A174-CCAC44372E6CQ55286600-5DEA7EBB-908C-436D-B330-C1DF039BCA94Q58803327-42C29B01-95FF-42F7-A3BB-CFC6218D5970
P2860
Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@ast
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@en
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@nl
type
label
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@ast
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@en
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@nl
prefLabel
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@ast
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@en
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@nl
P2093
P2860
P1433
P1476
Intravenous N-acetylcysteine f ...... randomized, controlled trials
@en
P2093
Lingling Cheng
Longxing Cao
Zhiliang Li
P2860
P304
P356
10.1371/JOURNAL.PONE.0055124
P407
P577
2013-01-30T00:00:00Z